• Excellence

  • Tenacious

  • Relentless

Media Release

Mar 18, 2024

CDE Clears IND Application for Therapeutic Candidate Targeting ATTR

The first in vivo gene editing drug using lipid nanoparticle to receive clinical approval in China

Share

e2_icon05.svg
e2_icon02.svg
e2_icon01.svg

LATESTNEWS